Semaglutide Dosage Chart Units: How to Convert Milligrams to Syringe Markings at Any Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• For compounded semaglutide at 5 mg/mL (the most common concentration), 0.25 mg equals 5 units, 0.5 mg equals 10 units, 1 mg equals 20 units, and 2.4 mg equals 48 units on a U-100 insulin syringe
• The unit count changes completely if your vial is 10 mg/mL, 2.5 mg/mL, or any other concentration, which is why reading your specific vial label is the single most important safety step
• "Units" is technically incorrect terminology for semaglutide (it's not insulin), but pharmacies use it because patients inject with U-100 insulin syringes where each marking represents 0.01 mL
• Most dosing errors happen during pharmacy transitions when concentration changes without patient notification, turning a previously correct "50 units" into either a double-dose or half-dose

Direct answer (40-60 words)

At the standard compounded concentration of 5 mg/mL, semaglutide doses convert as follows: 0.25 mg = 5 units, 0.5 mg = 10 units, 1 mg = 20 units, 1.7 mg = 34 units, 2.4 mg = 48 units. At 10 mg/mL these numbers halve. At 2.5 mg/mL they double. The concentration on your vial label determines every conversion.

Table of contents

1. Why semaglutide dosing uses "units" when it's not insulin
2. Complete unit conversion chart for all common concentrations
3. How to identify your vial's concentration in 15 seconds
4. The FormBlends 5-Question Pre-Injection Safety Protocol
5. Step-by-step syringe drawing technique for fractional doses
6. What most dosing charts get wrong about maintenance doses
7. The three failure modes of concentration-based dosing
8. When you should NOT rely on unit conversions
9. Storage, stability, and the 28-day rule
10. Dose escalation timeline and unit progression
11. FAQ
12. Sources

Why semaglutide dosing uses "units" when it's not insulin

The term "unit" has a specific pharmacological meaning: one unit of insulin is the biological equivalent of 34.7 micrograms of pure crystalline insulin. Semaglutide is a GLP-1 receptor agonist peptide with no insulin activity and no standardized unit-based potency measurement.

When a pharmacy writes "inject 20 units of semaglutide," they mean "draw to the 20-unit marking on a U-100 insulin syringe," which corresponds to 0.20 mL of liquid. The convention exists because U-100 insulin syringes are the only widely available injection devices with fine enough graduations to measure the tiny volumes semaglutide requires.

A U-100 insulin syringe is calibrated so that 100 units equals 1 mL. Each unit marking represents 0.01 mL (one-hundredth of a milliliter). For semaglutide, this creates a simple conversion: units ÷ 100 = milliliters.

The actual milligram dose you receive depends on concentration. If your vial contains 5 mg of semaglutide per mL, then 0.20 mL (20 units) delivers 1 mg. If the vial contains 10 mg per mL, that same 0.20 mL delivers 2 mg. Same syringe marking, double the drug.

This is why "how many units is 1 mg of semaglutide" has no universal answer. The answer is concentration-dependent, and concentration varies by pharmacy, by formulation, and sometimes by supply-chain availability.

Complete unit conversion chart for all common concentrations

The table below covers the four concentrations most U.S. compounding pharmacies use and the six standard semaglutide dose levels from initial titration through maintenance.

Concentration	0.25 mg	0.5 mg	1 mg	1.7 mg	2 mg	2.4 mg
2.5 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	40 units (0.40 mL)	68 units (0.68 mL)	80 units (0.80 mL)	96 units (0.96 mL)
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	34 units (0.34 mL)	40 units (0.40 mL)	48 units (0.48 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	17 units (0.17 mL)	20 units (0.20 mL)	24 units (0.24 mL)
12.5 mg/mL	2 units (0.02 mL)	4 units (0.04 mL)	8 units (0.08 mL)	13.6 units (0.136 mL)	16 units (0.16 mL)	19.2 units (0.192 mL)

A few patterns worth internalizing:

5 mg/mL is the industry standard because it balances dose accuracy with injection volume. At this concentration, every 0.1 mL (10 units) delivers 0.5 mg, and the most common maintenance dose of 2.4 mg comes out to a readable 48 units.

10 mg/mL concentrations are used when vial space is limited or when a pharmacy wants to fit a full titration schedule into a smaller multi-dose vial. The downside: starting doses fall below 5 units, which is hard to read accurately on most U-100 syringes. A 0.25 mg dose at 10 mg/mL is 2.5 units, and most syringes only have half-unit markings on 0.3 mL barrels.

2.5 mg/mL concentrations are occasionally used for patients who need very small dose adjustments or who are extremely sensitive to titration. The larger injection volumes (96 units for 2.4 mg) require a 1 mL syringe instead of the more common 0.5 mL barrel.

12.5 mg/mL concentrations are rare and typically appear only in custom compounding scenarios. Fractional unit doses (13.6 units, 19.2 units) require rounding, which introduces small dosing variability.

If your vial is 5 mg/mL, the mental math shortcut is: multiply the milligram dose by 20 to get units. So 1 mg × 20 = 20 units, 2.4 mg × 20 = 48 units.

If your vial is 10 mg/mL: multiply the milligram dose by 10. So 1 mg × 10 = 10 units, 2.4 mg × 10 = 24 units.

How to identify your vial's concentration in 15 seconds

The concentration appears on the vial label in one of three formats:

Format 1: "Semaglutide 5 mg/mL" The concentration is 5 mg per mL. This is the clearest format.

Format 2: "Semaglutide 25 mg / 5 mL" Divide the first number by the second: 25 ÷ 5 = 5 mg/mL.

Format 3: "Semaglutide for Injection, 10 mg" This format shows only the total drug content. The concentration depends on the reconstitution volume. Check the pharmacy's mixing instructions. If the instructions say "add 2 mL bacteriostatic water," the final concentration is 10 mg ÷ 2 mL = 5 mg/mL.

If your vial is pre-mixed (liquid, not powder), the concentration is printed somewhere on the vial, the carton, or the patient information sheet. If you can't find it, call the pharmacy before drawing a dose. Guessing the concentration is the single highest-risk step in self-administered compounded semaglutide.

Common labeling locations:

• Primary vial label (wrapped around the glass)
• Secondary label on the vial cap
• Carton exterior (the box the vial came in)
• Patient instruction sheet (often titled "Dosing Guide" or "Administration Instructions")
• Pharmacy portal or prescription details page

Some compounding pharmacies print concentration in tiny font below the drug name. If you're over 50 and the label font is 6-point, use your phone camera to zoom in rather than squinting.

The FormBlends 5-Question Pre-Injection Safety Protocol

We built this checklist after analyzing the most common points of failure in self-administered compounded GLP-1 therapy. Answer all five questions before every injection. If any answer is "no" or "I'm not sure," stop and resolve the issue.

Question 1: Can I state my vial's concentration out loud from memory? If you have to check the label, you don't know it well enough. Write the concentration in permanent marker on the vial cap the first time you use it.

Question 2: Does the liquid in the vial look identical to the last time I used it? Semaglutide should be clear and colorless to faintly straw-yellow. Cloudiness, particles, color change, or separation means degradation. Don't use it.

Question 3: Is this the same concentration as my last vial? Pharmacy switches and refills are the highest-risk moment for concentration errors. If this is a new vial from a new pharmacy or a new prescription, re-verify the unit conversion even if the milligram dose is the same.

Question 4: Can I explain why I'm drawing this specific unit count? "Because the chart says so" is not sufficient. You should be able to say: "I'm prescribed 1 mg, my vial is 5 mg/mL, so 1 mg ÷ 5 mg/mL = 0.2 mL = 20 units."

Question 5: Have I rotated my injection site from last week? Lipohypertrophy (tissue thickening from repeated injections in the same spot) reduces absorption consistency. Rotate between abdomen, thighs, and upper arms on a three-week cycle minimum.

[Diagram suggestion: flowchart with five decision diamonds, each labeled with one question. "No" or "Not sure" arrows lead to a red stop box reading "Resolve before injecting." All "Yes" arrows converge on a green box reading "Safe to proceed."]

This protocol takes 20 seconds and eliminates the majority of user-caused dosing errors we see in telehealth GLP-1 programs.

Step-by-step syringe drawing technique for fractional doses

The protocol below assumes a 5 mg/mL vial and a 1 mg dose (20 units). Adjust the unit count using the chart above for other doses and concentrations.

Materials needed:

• Compounded semaglutide vial (refrigerated, not frozen)
• U-100 insulin syringe, 0.5 mL or 1 mL barrel, 29- to 31-gauge needle
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Steps:

1. Wash hands with soap and water for 20 seconds. Dry completely.

1. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections sting more and can cause injection-site reactions.

1. Inspect the vial. Hold it up to a light. The solution should be clear with no floating particles, cloudiness, or discoloration. If anything looks wrong, don't use it.

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it.

1. Prepare the syringe. Remove the cap. Pull the plunger back to the 20-unit mark, drawing air into the barrel.

1. Insert the needle into the vial straight down through the center of the rubber stopper. Push the plunger to inject the air. This prevents vacuum formation.

1. Invert the vial so the needle tip is submerged in liquid. Keep the vial inverted and pull the plunger back slowly to the 20-unit mark.

1. Check for air bubbles. Small bubbles (1-2 mm) are cosmetic and harmless. Large bubbles displace medication. If you see a bubble larger than 3 mm, push the liquid back into the vial, tap the syringe to dislodge bubbles, and re-draw.

1. Verify the dose. Hold the syringe at eye level. The black rubber plunger tip (not the wide back end) should align exactly with the 20-unit line.

1. Withdraw the needle from the vial. Set the vial aside. Don't recap the needle.

1. Select an injection site. Acceptable sites: abdomen (at least 2 inches from the navel), front or outer thigh, back of the upper arm. Avoid areas with scars, moles, or visible veins.

1. Wipe the injection site with the second alcohol pad. Let it dry.

1. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle in one smooth motion. If you have very low body fat, use a 45-degree angle.

1. Inject slowly. Push the plunger steadily over 5 to 10 seconds. Fast injection increases injection-site pain.

1. Withdraw the needle. Release the skin pinch. Don't rub the site.

1. Dispose of the syringe immediately in a sharps container. Never recap.

1. Return the vial to the refrigerator. Mark the date of first use if this was the first draw.

The entire process takes 90 seconds to two minutes once you've done it three or four times.

What most dosing charts get wrong about maintenance doses

Most published semaglutide unit conversion charts stop at 2 mg because that's the FDA-approved maximum for Ozempic (the diabetes formulation). Wegovy, the weight-management formulation, goes to 2.4 mg. Compounded semaglutide prescribed off-label for weight management often follows the Wegovy schedule, which means patients need accurate unit conversions for 2.4 mg.

The second common error: charts assume a single concentration (usually 5 mg/mL) without explicitly stating the assumption. A patient Googling "how many units is 1 mg of semaglutide" lands on a chart that says "20 units" without the critical qualifier "at 5 mg/mL." If their vial is 10 mg/mL, they've just drawn double the dose.

The third error is rounding. At 5 mg/mL, the 1.7 mg dose (Wegovy's second-to-last titration step) converts to 34 units (0.34 mL). Some charts round this to 35 units "for simplicity." That's a 3% over-dose, which is usually clinically irrelevant but violates the principle that patients should inject exactly what's prescribed. If the math yields 34 units, draw 34 units. U-100 syringes have 1-unit graduations for a reason.

The fourth error: failing to address what happens when the prescribed dose falls between syringe markings. At 10 mg/mL concentration, a 0.75 mg dose is 7.5 units. Standard U-100 syringes mark whole units. A 0.3 mL barrel syringe has half-unit marks, so 7.5 units is readable. A 1 mL barrel syringe does not, so you'd round to 7 or 8 units. Most charts don't specify which syringe barrel size to use for which dose range.

What we see most often in FormBlends patient consultations: patients receive a new vial at a different concentration after a pharmacy switch, continue drawing the same unit count they've been using for months, and either under-dose or over-dose for 2 to 4 weeks before noticing the error. The pattern is consistent enough that we now send a concentration-verification prompt via SMS every time a patient's prescription is transferred to a new pharmacy.

The three failure modes of concentration-based dosing

Failure Mode 1: The Silent Pharmacy Switch

A patient starts semaglutide with Pharmacy A, which dispenses 5 mg/mL. The prescribed dose is 1 mg weekly, so the patient draws 20 units. After three months, Pharmacy A has a supply issue and the prescription auto-transfers to Pharmacy B, which dispenses 10 mg/mL. The patient receives the new vial, sees "semaglutide 1 mg weekly" on the label, and continues drawing 20 units. At 10 mg/mL, 20 units is 2 mg, double the prescribed dose.

The patient experiences severe nausea, assumes it's normal titration side effects, and continues for two weeks before calling the provider. By the time the error is caught, they've injected eight weeks' worth of medication in four weeks.

The fix: every new vial gets a concentration check before the first draw, even if it's a refill from the same pharmacy. Write the concentration and unit count on the vial cap in permanent marker.

Failure Mode 2: The Reconstitution Miscalculation

A patient receives a 10 mg lyophilized (freeze-dried) semaglutide vial with instructions to reconstitute with 2 mL bacteriostatic water, yielding 5 mg/mL. The patient adds 1 mL of water instead (misreading "2 mL" as "2 vials" or simply pouring until the powder dissolves). The actual concentration is now 10 mg/mL, double the intended strength.

The patient follows the dosing chart for 5 mg/mL and injects twice the prescribed dose every week until the vial is empty.

The fix: reconstitution instructions should be read twice, out loud, before opening the water vial. If the instructions say "add 2 mL," measure 2 mL in the syringe and verify the volume before injecting it into the powder. See our reconstitution guide for the full protocol.

Failure Mode 3: The Fractional-Dose Rounding Error

A patient at 10 mg/mL concentration is prescribed 0.75 mg weekly (an off-label micro-titration step sometimes used for patients with severe GI sensitivity). The correct dose is 7.5 units. The patient's 1 mL U-100 syringe has whole-unit markings only. The patient rounds up to 10 units "to be safe," assuming more is better.

Over 12 weeks, the patient has injected 10 mg instead of 9 mg, a cumulative 11% over-dose. The patient plateaus on weight loss earlier than expected and assumes the medication has stopped working.

The fix: if your prescribed dose falls between unit markings on your syringe, get a 0.3 mL barrel syringe with half-unit markings, or ask your provider to adjust the dose to a whole-unit equivalent.

When you should NOT rely on unit conversions

Unit-based dosing works well for stable, single-concentration regimens. It breaks down in four scenarios:

Scenario 1: You're mixing two concentrations from different vials. Some patients receive overlapping prescriptions during a pharmacy transition and have two vials of different concentrations in the refrigerator. Never draw from two vials in the same week unless your provider has given you a specific protocol. The concentration mismatch makes unit-based dosing unreliable.

Scenario 2: You're splitting a weekly dose into two injections. Semaglutide's 7-day half-life is designed for weekly dosing. Some patients split doses (e.g., 1.2 mg on Monday, 1.2 mg on Thursday instead of 2.4 mg once weekly) to reduce side effects. This is a clinical decision that requires provider guidance. If you're splitting, the unit count per injection is half the weekly total, but the pharmacokinetics change and you may need dose adjustment.

Scenario 3: Your vial has been temperature-cycled. If a vial has been left at room temperature for more than 24 hours, frozen, or exposed to heat above 86°F, the peptide may have degraded. Degraded semaglutide doesn't change concentration, but it loses potency. Unit conversions remain mathematically correct, but the clinical effect diminishes. Discard temperature-compromised vials.

Scenario 4: You're using a non-standard syringe. Unit conversions assume a U-100 insulin syringe. If you're using a tuberculin syringe (marked in mL only, not units), a U-500 insulin syringe (marked in units but calibrated differently), or any other device, the conversion chart doesn't apply. Stick with U-100 syringes unless your provider specifies otherwise.

In all four scenarios, contact your provider before injecting. Guessing is not a safe fallback.

Storage, stability, and the 28-day rule

Unopened vials: store at 36 to 46°F (2 to 8°C) until the expiration date printed on the label. Don't freeze. Freezing denatures the peptide and makes it inactive.

After first use: most compounding pharmacies label semaglutide vials "discard 28 days after first use" when stored refrigerated. This is a conservative USP 797 guideline for medium-risk compounded sterile preparations. Some pharmacies use 21 days. The shorter window applies if the formulation lacks a preservative or if the pharmacy's beyond-use date testing supports a shorter period.

Room temperature stability: compounded semaglutide can sit at room temperature (up to 77°F) for up to 24 hours without significant degradation. This covers travel, accidental overnight counter storage, or a brief power outage. Beyond 24 hours, refrigerate immediately or discard.

Travel: use an insulated medication travel case with a reusable gel ice pack (not direct ice, which can freeze the vial). TSA allows medically necessary liquids in carry-on bags. Bring the prescription label. If you're traveling for more than a week, some pharmacies can provide a smaller vial or pre-filled syringes.

Discoloration: semaglutide is colorless to faintly yellow. A pink, orange, or red tint usually indicates added cyanocobalamin (vitamin B12), which some compounding formulations include. If your vial is colored and the label doesn't mention B12, call the pharmacy. Unexpected color change can indicate contamination or oxidation.

Particulates: any visible particles, cloudiness, or sediment means the vial is compromised. Don't inject. Peptides can aggregate if temperature-cycled or stored past their stability window. Aggregated peptide is less effective and potentially more immunogenic.

Dose escalation timeline and unit progression

The standard semaglutide titration schedule for weight management follows the Wegovy protocol: start at 0.25 mg weekly, increase every four weeks until reaching 2.4 mg weekly. The table below shows unit progression at 5 mg/mL concentration.

Week	Dose (mg)	Units at 5 mg/mL	Units at 10 mg/mL	Clinical goal
1-4	0.25	5	2.5	GI tolerance adaptation
5-8	0.5	10	5	Early appetite suppression
9-12	1.0	20	10	Therapeutic effect onset
13-16	1.7	34	17	Plateau check
17-20	2.4	48	24	Maintenance dose

Some providers use slower titration (8-week intervals instead of 4-week) for patients with a history of severe GI side effects. Others add an intermediate 0.75 mg step between 0.5 mg and 1 mg. These are clinical judgment calls based on individual tolerance.

The unit count increases at each step, but the injection volume remains small. Even at the maximum 2.4 mg dose, you're injecting 0.48 mL (48 units) at 5 mg/mL, which is less than half a milliliter. For reference, a standard insulin injection for a type 1 diabetic can be 0.5 to 1 mL per dose.

FAQ

What does "units" mean for semaglutide? "Units" refers to the markings on a U-100 insulin syringe, where 100 units equals 1 mL. It's borrowed terminology from insulin dosing. For semaglutide, units are a volume measurement, not a potency measurement.

How many units is 0.5 mg of semaglutide? At 5 mg/mL concentration, 0.5 mg is 10 units. At 10 mg/mL it's 5 units. At 2.5 mg/mL it's 20 units. The answer depends on your vial's concentration.

How many units is 1 mg of semaglutide? At 5 mg/mL, 1 mg is 20 units. At 10 mg/mL it's 10 units. At 2.5 mg/mL it's 40 units. Check your vial label for the exact concentration.

How many units is 2.4 mg of semaglutide? At 5 mg/mL, 2.4 mg is 48 units. At 10 mg/mL it's 24 units. This is the maximum FDA-approved dose for weight management (Wegovy) and a common maintenance dose for compounded semaglutide.

Can I use a U-500 insulin syringe for semaglutide? No. U-500 syringes are calibrated differently (1 unit on a U-500 syringe equals 5 units on a U-100 syringe). Using a U-500 syringe would deliver five times the intended dose. Only use U-100 syringes for semaglutide.

What if my dose falls between unit markings? Use a 0.3 mL U-100 syringe, which has half-unit markings. If your dose still falls between markings (e.g., 7.5 units on a whole-unit syringe), round to the nearest mark or ask your provider to adjust the dose to a whole-unit equivalent.

How do I convert mL to units? Multiply milliliters by 100. So 0.25 mL = 25 units, 0.48 mL = 48 units. This works for any U-100 syringe regardless of what medication you're injecting.

How do I convert mg to units for semaglutide? Divide the milligram dose by the concentration (mg/mL) to get milliliters, then multiply by 100 to get units. Example: 1 mg ÷ 5 mg/mL = 0.2 mL × 100 = 20 units.

What size syringe should I use? For doses under 30 units, use a 0.3 mL syringe (holds up to 30 units). For doses between 30 and 50 units, use a 0.5 mL syringe. For doses above 50 units, use a 1 mL syringe. Smaller barrels have finer markings and are easier to read.

Why does my pharmacy's unit count differ from online charts? Online charts assume a specific concentration (usually 5 mg/mL). If your pharmacy uses a different concentration, the unit count changes. Always use your vial's concentration, not a generic chart.

Can I draw multiple weeks' worth of doses at once? No. Pre-filling syringes increases contamination risk and degrades the peptide. Semaglutide is stable in a sealed vial for 28 days but degrades faster in a syringe. Draw each dose immediately before injection.

What happens if I inject the wrong number of units? Small errors (1-2 units) usually have no clinical effect. Errors above 20% of the prescribed dose can increase side effects (nausea, vomiting, diarrhea) or reduce efficacy. If you've injected significantly more or less than prescribed, contact your provider.

How accurate are U-100 syringe markings? ISO 8537 specifies a tolerance of ±5% for insulin syringes. For a 20-unit draw, that's ±1 unit, which is clinically insignificant for semaglutide. Manufacturing variance is not a meaningful source of dosing error.

Do I need to prime the syringe before injecting? No. "Priming" (expelling a small amount of medication to remove air) is unnecessary for subcutaneous injections. Small air bubbles in the syringe are harmless. Only expel air if a large bubble is displacing medication.

Can I reuse a syringe? No. Syringes and needles are single-use only. Reusing increases infection risk, dulls the needle (making injections more painful), and can introduce contamination into the vial.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP-NF. 2024.
6. United States Pharmacopeia. Chapter 8: Insulin Syringes and Needles. USP-NF. 2024.
7. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
8. Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
9. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet. 2024.
10. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
11. Kosiborod MN et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.